Zinc transporter 8 Antibodies

Zinc transporter 8 (SLC30A8)

Facilitates the accumulation of zinc from the cytoplasm into intracellular vesicles, being a zinc-efflux transporter. May be a significant component for providing zinc to insulin maturation and/or storage processes in insulin-secreting pancreatic beta- cells.

.

Gene Information

Human
Gene Name:	SLC30A8
Uniprot:	Q8IWU4
Entrez:	169026

Family

Belongs to:
cation diffusion facilitator (CDF) transporter (TC 2.A.4) family

Alternative Names

SLC30A8; solute carrier family 30 (zinc transporter), member 8; Solute carrier family 30 member 8; zinc transporter 8; zinc transporter ZnT-8; ZnT8; ZnT-8; ZNT8ZnT-8

Molecular Weight

Mass (kDA):
40.755 kDA

Genomic Context

Human
Location:	8q24.11
Sequence:	8; NC_000008.11 (116950217..117176714)

Tissue Specificity

In the endocrine pancreas, expressed in insulin-producing beta cells. Expressed at relatively high levels in subcutaneous fat tissue from lean persons; much lower levels in visceral fat, whether from lean or obese individuals, and in subcutaneous fat tissue from obese individuals. Expressed in peripheral blood mononuclear cells, including T-cells and B-cells, with great variation among individuals ranging from negative to strongly positive.

Subcellular Localizations

Cell membrane; Multi-pass membrane protein. Cytoplasmic vesicle, secretory vesicle membrane; Multi-pass membrane protein. Associated with insulin and glucagon secretory granules.

Diseases

• Diabetes Mellitus
• Diabetes Mellitus, Non-insulin-dependent
• Diabetes Mellitus, Insulin-dependent
• Autoimmunity
• Insulin Resistance
• Obesity
• Insulin Sensitivity
• Autoimmune Reaction
• Impaired Glucose Tolerance
• Hyperglycemia
• Cholangiocarcinoma
• Prediabetes Syndrome

• Diabetes, Autoimmune
• Dysequilibrium Syndrome
• Complications Of Diabetes Mellitus
• Autoimmune Diseases
• Insulinoma
• Gestational Diabetes
• Atherosclerosis

Interacting Proteins

• CREB3L1

Pathways

• Secretion
• Insulin Secretion
• Pathogenesis
• Glucose Homeostasis
• Transport
• Insulin Processing
• Translation
• Glucagon Secretion
• Secretory Pathway
• Cell Development
• Localization
• Regeneration
• Stem Cell Differentiation

• Immune Response
• Hypersensitivity
• Flight
• Cell Cycle
• Cell Differentiation
• Exocytosis
• Hormone Secretion

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/SLC30A8

Boster Bio - Best Uses Of The SLC30A8 Marker

The best way to maximize the use of this primary antibody is to first learn about its clinical applications and credit information. You can submit your results to a species or an application as a scientist and get credit for them. These credits are available to all scientists worldwide. These credits are available to all scientists worldwide.

Boster Bio's Anti-Zinc Transporter 8. SLC30A8 Primary Antibody

Boster Bio's Anti-ZinC Transporter 8 Primary Immunoglobulin SLC30A8 was created to detect antibodies against ZnT8 dimerization. Purifying rabbit IgG obtained from goats was the method used to create the anti-ZnT8 antibody. After incubation of alpha-chloronaphthol with TBS-MT, we added 10 vol H2O2 to the mixture and then added serial concentrations TrxZnT8biotin.

The antibody reacts with zinc within the cytoplasm. It is a zinc-eflux transporter and may play an important role in insulin maturation and storage. This protein is a member of the cation diffusion facilitator transportationer family and the SLC30A subdivision. Alternatively, the gene can also be spliced into two forms: SLC30A8.

The pTrx genetic was used to generate the protein in E. coli GI724 strain. The protein was then insoluble in 8M urea in pH 0.1 M Tris. The protein was then purified via affinity chromatography. The anti–Trx antibodies in resin recognized the Trx portion. The resin had a high ability to separate the protein form most contaminating protein.

In an assay with radioligand, the primary antibody against ZnT8A was raised. The RBA displayed high specificity and sensitivity. The antibody was tested in human sera using radiolabeled autoantigen recombinantly added. These assays do not require cell-free expression systems and are therefore not suitable for widespread usage.

Clinical applications

Multiple studies with human induced pluripotent stem cells-derived beta cells have confirmed the validity of the SLC30A8 gene. Due to nonsense mediated decay and reduced Zn2+ content, the R138X allele reduced SLC30A8 gene expression. Knockdown in human beta cells of SLC30A8 resulted in increased insulin secretion as well as processing of proinsulin. Mice with the R138X variant had higher insulin secretion in high-fat diets. In a rat insulinoma cell, the protein showed punctate distribution of the protein and localization to secretorygranules.

The SLC30A8 protein regulates the SLC30A8 genes. People with type 2 diabetes have a higher level of SLC30A8 expression. This is due to the presence of methyl groups at certain genomic sites. Hypomethylation at certain genomic sites can be a sign of T2D early warning signs. The SLC30A8 diabetes marker has multiple clinical applications.